Clinical observation of Tongmai Jiangtang capsule combined with Dulotide in treating obese type 2 diabetes mellitus
Objective:To investigate the clinical effect and safety of Tongmai Jiangtang capsule combined with Dulotide in the treatment of obese type 2 diabetes mellitus.Methods:The clinical data of 87 obese patients with type 2 diabetes admitted to our hospital from January 2022 to September 2023 were retrospectively collected.According to different treatment methods,the patients were divided into control group(43 cases)and study group(Tongmai Jiangtang capsule combined with Dula glycopeptide treatment,44 cases).The efficacy,blood glucose related indexes(HBA1c,fasting blood glucose,2 hours postmeal blood glucose),TCM syndrome score,hemorheology indexes and adverse events of the two groups were analyzed and compared.Results:After 2 months of treatment,the total effective rate of the study group was significantly higher than that of the control group(P<0.05).The HBA1c,fasting blood glucose and 2 hours postprandial blood glucose of the study group were significantly lower than those of the control group(P<0.05).After treatment,the scores of TCM symptoms in both groups were significantly decreased,and the scores of TCM symptoms in the study group were significantly lower than those in the control group(P<0.05).The hemorheology indexes of the study group were significantly better than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Tongmai Jiangtang capsule combined with Dula glycopeptide in the treatment of obesity type 2 diabetes can improve clinical efficacy,control blood sugar level,improve TCM symptoms,reduce blood viscosity,improve microcirculation,and do not increase adverse reactions.
NETL
NSTL
万方数据
